Ray Y. Chen

Ray Y. Chen

Auto-generated profile, based on publicly available information

Ray Y. Chen

Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MLMyungsun Lee
Myungsun Lee
JLJongseok Lee
Jongseok Lee
MCMatthew W. Carroll
Matthew W. Carroll
HCHongjo Choi
Hongjo Choi
SMSeonyeong Min
Seonyeong Min
CIClifton Earl Barry, III
Clifton Earl Barry, III
Linezolid has antimycobacterial activity in vitro and is increasingly used for patients with highly drug-resistant tuberculosis. We enrolled 41 patients who had sputum-culture–positive extensively drug-resistant (XDR) tuberculosis and who had not had a response to any available chemotherapeutic option during the previous 6 months. Patients were randomly assigned to linezolid therapy that started immediately or after 2 months, at a dose of 600 mg per day, without a change in their background regimen. The primary end point was the time to sputum-culture conversion on solid medium, with data censored 4 months after study entry. After confirmed sputum-smear conversion or 4 months (whichever came first), patients underwent a second randomization to continued linezolid therapy at a dose of 600 mg per day or 300 mg per day for at least an additional 18 months, with careful toxicity monitoring. By 4 months, 15 of the 19 patients (79%) in the immediate-start group and 7 of the 20 (35%) in the delayed-start group had culture conversion (P=0.001). Most patients (34 of 39 [87%]) had a negative sputum culture within 6 months after linezolid had been added to their drug regimen. Of the 38 patients with exposure to linezolid, 31 (82%) had clinically significant adverse events that were possibly or probably related to linezolid, including 3 patients who discontinued therapy. Patients who received 300 mg per day after the second randomization had fewer adverse events than those who continued taking 600 mg per day. Thirteen patients completed therapy and have not had a relapse. Four cases of acquired resistance to linezolid have been observed. Linezolid is effective at achieving culture conversion among patients with treatment-refractory XDR pulmonary tuberculosis, but patients must be monitored carefully for adverse events. (Funded by the National Institute of Allergy and Infectious Diseases and the Ministry of Health and Welfare, South Korea; ClinicalTrials.gov number, NCT00727844.)

1 July 2011 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FZFujie Zhang
Fujie Zhang
ZDZhihui Dou
Zhihui Dou
YMYe Ma
Ye Ma
YZYao Zhang
Yao Zhang
YZYan Zhao
Yan Zhao
RCRay Y Chen
Ray Y Chen

3 December 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RCRay Y. Chen
Ray Y. Chen
LDLori E. Dodd
Lori E. Dodd
MLMyungsun Lee
Myungsun Lee
PPPraveen Paripati
Praveen Paripati
DHDima A Hammoud
Dima A Hammoud
CIClifton Earl Barry, III
Clifton Earl Barry, III
Definitive clinical trials of new chemotherapies for treating tuberculosis (TB) require following subjects until at least 6 months after treatment discontinuation to assess for durable cure, making these trials expensive and lengthy. Surrogate endpoints relating to treatment failure and relapse are currently limited to sputum microbiology, which has limited sensitivity and specificity. We prospectively assessed radiographic changes using 2-deoxy-2-[18F]-fluoro-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) at 2 and 6 months (CT only) in a cohort of subjects with multidrug-resistant TB, who were treated with second-line TB therapy for 2 years and then followed for an additional 6 months. CT scans were read semiquantitatively by radiologists and were computationally evaluated using custom software to provide volumetric assessment of TB-associated abnormalities. CT scans at 6 months (but not 2 months) assessed by radiologist readers were predictive of outcomes, and changes in computed abnormal volumes were predictive of drug response at both time points. Quantitative changes in FDG uptake 2 months after starting treatment were associated with long-term outcomes. In this cohort, some radiologic markers were more sensitive than conventional sputum microbiology in distinguishing successful from unsuccessful treatment. These results support the potential of imaging scans as possible surrogate endpoints in clinical trials of new TB drug regimens. Larger cohorts confirming these results are needed.

3 December 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MCM. Teresa Coleman
M. Teresa Coleman
RCRay Y. Chen
Ray Y. Chen
MLMyungsun Lee
Myungsun Lee
PLPhilana Ling Lin
Philana Ling Lin
LDLori E. Dodd
Lori E. Dodd
JFJoAnne L. Flynn
JoAnne L. Flynn
Oxazolidinone antibiotics such as linezolid have shown significant therapeutic effects in patients with extensively drug-resistant (XDR) tuberculosis (TB) despite modest effects in rodents and no demonstrable early bactericidal activity in human phase 2 trials. We show that monotherapy with either linezolid or AZD5847, a second-generation oxazolidinone, reduced bacterial load at necropsy in Mycobacterium tuberculosis–infected cynomolgus macaques with active TB. This effect coincided with a decline in 2-deoxy-2-[18F]-fluoro-d-glucose positron emission tomography (FDG PET) imaging avidity in the lungs of these animals and with reductions in pulmonary pathology measured by serial computed tomography (CT) scans over 2 months of monotherapy. In a parallel phase 2 clinical study of linezolid in patients infected with XDR-TB, we also collected PET/CT imaging data from subjects receiving linezolid that had been added to their failing treatment regimens. Quantitative comparisons of PET/CT imaging changes in these human subjects were similar in magnitude to those observed in macaques, demonstrating that the therapeutic effect of these oxazolidinones can be reproduced in this model of experimental chemotherapy. PET/CT imaging may be useful as an early quantitative measure of drug efficacy against TB in human patients.

1 November 2015 in EBioMedicine
Verified
Journal Article
Open access
TSTaeksun Song
Taeksun Song
MLMyungsun Lee
Myungsun Lee
HJHan-Seung Jeon
Han-Seung Jeon
YPYumi Park
Yumi Park
LDLori E. Dodd
Lori E. Dodd
RCRay Y. Chen
Ray Y. Chen
Long-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospective, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially monitored the translational competence of mitochondria isolated from peripheral blood of participants by determining the cytochrome c oxidase/citrate synthase activity ratio. We compared this ratio with AEs associated with mitochondrial dysfunction. Linezolid trough concentrations were determined for 38 participants at both 600 mg and 300 mg doses. Those on 600 mg had a significantly higher risk of AE than those on 300 mg (HR 3·10, 95% CI 1·23-7 · 86). Mean mitochondrial function levels were significantly higher in patients before starting linezolid compared to their concentrations on 300 mg (P = 0·004) or 600 mg (P < 0·0001). Increasing mean linezolid trough concentrations were associated with lower mitochondrial function levels (Spearman's ρ = - 0.48; P = 0.005). Mitochondrial toxicity risk increased with increasing linezolid trough concentrations, with all patients with mean linezolid trough > 2 μg/ml developing an AE related to mitochondrial toxicity, whether on 300 mg or 600 mg. Therapeutic drug monitoring may be useful to prevent the development of mitochondrial toxicity associated with long-term linezolid use.

1 October 2013 in The Lancet
Verified
Journal Article
Closed access
ZJZhongwei Jia
Zhongwei Jia
YMYurong Mao
Yurong Mao
FZFujie Zhang
Fujie Zhang
YRYuhua Ruan
Yuhua Ruan
YMYe Ma
Ye Ma
YSYiming Shao
Yiming Shao